05-05-EY-YE-Webinar-OnDemandCTA.jpg

Parthenon-EY and YourEncore recently conducted a nationwide survey of life sciences experts to query them on recent market trends, uncover their points of view on potential regulations, refine their current business models and gain insights into what discovery efforts might yield better results. With all the rhetoric surrounding the drug industry from political, news and personal channels, we wanted to know what “those who know” think of various ways to improve the system.

We asked 10 simple questions, soliciting input from more than 50 past and present industry executives and Experts from pharmaceutical, consulting and pharmacy backgrounds. What we heard was informative, provocative and in some cases unsurprising — but important to consider. 

In this webinar, we hosted a roundtable with YourEncore Experts Peter Pitts, Dr. Lorna Speid, and Dr. June Almenoff, with EY's Managing Director of the EY-Parthenon Alliance, Alex Jung, as a moderator, to review the survey results and discuss their perspectives on the state of the life sciences industry.


Dr. June Almenoff is an independent drug development consultant and biopharma board director.  Previously, Dr. Almenoff was the President and CMO of Furiex Pharmaceuticals, which was acquired by Forest Laboratories for $1.2B in 2014, and the VP of Clinical Safety and Risk Management for GSK.  Dr. Almenoff also served as an Executive in Residence at Hatteras Venture Partners.

Peter J. Pitts is an authority on global regulatory issues and an Executive Partner at YourEncore. He is a former FDA Associate Commissioner, the Chief Regulatory Officer for Adherent Health Strategies, and the President of the Center for Medicine in the Public Interest, a policy institute he founded in 2004.

Dr. Lorna Speid is President, Speid & Associates, Founder and Chairman of the Board,  Putting Rare Disease Patients First, Founder and Co-chair of the Drug Development Boot Camp®, Author of  Clinical Trials: What Patients and Healthy Volunteers Need to  Know, published by Oxford University Press. Dr. Speid earned her Ph.D. in Safety Assessment of Medicines, Pre and Post Marketing, and has served on the NIH Committee for Therapeutics for Rare and Neglected Diseases.

Alex Jung is a managing director in the Parthenon-EY practice of Ernst & Young LLP, where she works primarily on strategic transformation projects. Alex has worked with many health care and life sciences companies across the country and has developed and implemented large-scale plan design and funding strategies such as the introduction of innovative consumer-driven health care plans, health savings accounts and health improvement initiatives, including on-site pharmacies and clinics for her former clients.   


Ernst & Young LLP and YourEncore have a strategic alliance to provide end-to-end offerings designed to help life sciences and consumer products clients accelerate product development, strengthen regulatory compliance, and improve productivity. This relationship unites EY management consulting, transaction advisory, and tax services with the real world experience of YourEncore’s expansive network of on-demand industry experts to provide a wide range of services to help clients innovate, drive growth, manage risk, and comply with increasing regulatory challenges.